Protection offered by GSK malaria vaccine fades over time<p><a href="http://news.yahoo.com/protection-offered-gsk-malaria-vaccine-fades-over-time-210346946--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/jcAj6ypYs47Sm1GO.cuc9A--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-03-20T210346Z_1_CBRE92J1MID00_RTROPTP_2_GLAXO-RESULTS.JPG" width="130" height="86" alt="A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results" align="left" title="A GlaxoSmithKline logo is seen outside one of its buildings in west London, ahead of company results" border="0" /></a>By Kate Kelland and Gene Emery LONDON/NEW YORK (Reuters) - The effectiveness of an experimental malaria vaccine developed by GlaxoSmithKline wanes over time, with the shot protecting only 16.8 percent of children over four years, according to trial data. The disappointing results for RTS,S - the world's first potential malaria vaccine - raise further questions about whether it can make a difference in the fight against the disease, a major cause of illness and death among children in sub-Saharan Africa. ...</p><br clear="all"/>
Source: Protection offered by GSK malaria vaccine fades over time (http://news.yahoo.com/protection-offered-gsk-malaria-vaccine-fades-over-time-210346946--finance.html)